2025-06-27
Peter Thiel is utterly wrong about Alzheimer's
The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal founder Peter Thiel. There's a reason it was published in the opinion section.
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-03-30
Peter Thiel reportedly warned Sam Altman about AI safety conflicts shortly before the OpenAI crisis
Fresh reporting shows deeper tensions at OpenAI than previously known, with investor Peter Thiel warning Sam Altman about internal conflicts shortly before his November 2023 dismissal.<br /> The [...]
2025-05-16
The FDA clears the first blood test for diagnosing Alzheimer's disease
There's a new way to screen for early detection of Alzheimer's disease. On Friday, the Food and Drug Administration (FDA) cleared the first blood test for the disorder. Fujirebio Diagnostics [...]
2025-09-30
The Real Stakes, and Real Story, of Peter Thiel's Antichrist Obsession
Thirty years ago, a peace-loving Austrian theologian spoke to Peter Thiel about the apocalyptic theories of Nazi jurist Carl Schmitt. They've been a roadmap for the billionaire ever since. [...]
2025-11-13
Forrester: Gen AI is a chaos agent, models are wrong 60% of the time
The shark from Jaws attacked without warning, showing how an apex predator exploits chaos to create lethal, devastating harm on its prey. Now, Forrester says, gen AI has become that predator in the ha [...]
2025-03-27
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s
Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]
2025-03-28
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval
The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it co [...]